Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...

The collaboration will span over 200 Apollo clinics and involve 300 medical practitioners, focusing on patient education, ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

Thai patients gain faster access to next-generation treatments as Zuellig and Lilly deepen their healthcare partnership.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...